PHP
VYGR icon

Parkman Healthcare Partners’s Voyager Therapeutics VYGR Stock Holding History

Parkman Healthcare Partners’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-60,322
Closed -$467K – 105
2023
Q3 		$467K Buy
60,322
+2,441
+4% +$22.3K 0.09% 101
2023
Q2 		$663K Buy
+57,881
New +$599K 0.11% 91

Other funds holding VYGR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Parkman Healthcare Partners's VYGR Position: Q4 2023 in Review

Parkman Healthcare Partners sold out of Voyager Therapeutics (VYGR) in Q4 2023, closing a stake of 60,322 shares — an estimated $467K sold.

Parkman Healthcare Partners first reported a position in VYGR in Q2 2023 and held it in 2 quarters. The position peaked at $663K in Q2 2023. 107 funds tracked by Wall St. Rank hold VYGR as of Q4 2023.

  • Parkman Healthcare Partners reported no remaining Voyager Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Parkman Healthcare Partners sold 60,322 Voyager Therapeutics shares in Q4 2023, an estimated $467K.
  • Parkman Healthcare Partners first reported a position in Voyager Therapeutics in Q2 2023 and held it in 2 quarters.
  • Parkman Healthcare Partners's Voyager Therapeutics position peaked at $663K in Q2 2023.
  • 107 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q4 2023.

Based on Parkman Healthcare Partners's 13F filing for Q4 2023, filed 14 Feb 2024.